| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006177119 |
| P356 | DOI | 10.1023/A:1008878628326 |
| P698 | PubMed publication ID | 10751801 |
| P2093 | author name string | DeSilvey DL | |
| P2860 | cites work | GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico | Q28237540 |
| Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty | Q28242220 | ||
| A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group | Q28245560 | ||
| A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators | Q28245573 | ||
| An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 | ||
| Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri | Q28277512 | ||
| Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty | Q28282447 | ||
| Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty | Q28285343 | ||
| Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors | Q28294390 | ||
| Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Early and late ischemic complications of PTCA. | Q33568340 | ||
| Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial | Q33611581 | ||
| Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. | Q33856848 | ||
| Angiographic progression of coronary artery disease and the development of myocardial infarction | Q34176874 | ||
| Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology | Q34308581 | ||
| Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator | Q34308795 | ||
| Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty | Q34336722 | ||
| Aspirin as an antiplatelet drug | Q34338650 | ||
| A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group | Q34360479 | ||
| A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents | Q34374902 | ||
| Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, E | Q34407296 | ||
| Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials | Q34560241 | ||
| Calcium channel blockers in acute myocardial infarction and unstable angina: an overview | Q35718583 | ||
| The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 | ||
| Advances in coronary angioplasty | Q36825488 | ||
| Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents | Q37711747 | ||
| A macro and micro view of coronary vascular insult in ischemic heart disease. | Q37950544 | ||
| Unstable angina and coronary angioplasty | Q37950551 | ||
| Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. | Q39418124 | ||
| Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy | Q39453641 | ||
| Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting | Q70790002 | ||
| A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation | Q70866645 | ||
| The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions | Q70894140 | ||
| Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma | Q70897441 | ||
| Three-year follow-up after implantation of metallic coronary-artery stents | Q70920436 | ||
| Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: a quantitative angiographic analysis | Q70993101 | ||
| Three-year clinical follow-up after Palmaz-Schatz stenting | Q71020151 | ||
| Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death | Q71306624 | ||
| Antiplatelet therapy | Q71396795 | ||
| Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial | Q71493537 | ||
| Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis | Q71518095 | ||
| Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification | Q39528137 | ||
| Use of nitrates in the treatment of unstable and variant angina. | Q39665911 | ||
| Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease | Q40395727 | ||
| Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor | Q40421130 | ||
| Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model | Q40511655 | ||
| Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine | Q40518648 | ||
| Recognition and treatment of unstable angina | Q40931962 | ||
| Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non-Q-wave myocardial infarction | Q40936290 | ||
| Subacute stent thrombosis: evolving issues and current concepts | Q40943354 | ||
| Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor | Q40966386 | ||
| Fibrin-selective thrombolytic therapy for acute myocardial infarction | Q40968437 | ||
| Thrombosis in ischemic heart disease | Q41014378 | ||
| Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease | Q41017012 | ||
| Antiplatelet and anticoagulant use after myocardial infarction | Q41046059 | ||
| Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective | Q41073647 | ||
| Cumulative meta-analysis of therapeutic trials for myocardial infarction | Q41112231 | ||
| 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. | Q41123265 | ||
| Coronary intervention: risk stratification and management of abrupt coronary occlusion | Q41162636 | ||
| Clinical trials of Hirulog in patients undergoing high-risk percutaneous transluminal coronary angioplasty | Q41186639 | ||
| Immediate and follow-up results of the conservative coronary angioplasty strategy for unstable angina pectoris | Q41847039 | ||
| Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group | Q42064869 | ||
| Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes | Q42281372 | ||
| Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms | Q43479171 | ||
| Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group | Q43622066 | ||
| Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization | Q44612131 | ||
| Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry | Q45623159 | ||
| Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis | Q46145924 | ||
| Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa | Q46581809 | ||
| A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group | Q47303123 | ||
| Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) | Q47306075 | ||
| Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study | Q47324562 | ||
| Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction | Q47331075 | ||
| Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. | Q51004501 | ||
| Correlation of angiographic morphology and clinical presentation in unstable angina. | Q52524341 | ||
| Nitrates in myocardial infarction: a current perspective. | Q52870653 | ||
| A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators. | Q52889936 | ||
| Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. | Q54022849 | ||
| Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. | Q54131118 | ||
| Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. | Q54357272 | ||
| A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes | Q56945341 | ||
| Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months | Q56945638 | ||
| MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man | Q58481521 | ||
| Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood. Effects of different stenoses on thrombus growth | Q60924791 | ||
| Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction | Q68123206 | ||
| Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group | Q68158313 | ||
| Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction | Q68602036 | ||
| Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry | Q68902953 | ||
| Heparin-induced thrombocytopenia | Q69505793 | ||
| RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 | Q69755626 | ||
| Aspirin, heparin, or both to treat acute unstable angina | Q70216460 | ||
| Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity | Q70398354 | ||
| Reduced thiols and the effect of intravenous nitroglycerin on platelet aggregation | Q70401832 | ||
| Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy | Q70427257 | ||
| A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction | Q70562086 | ||
| Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups | Q70562091 | ||
| Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control study | Q70601597 | ||
| Coronary stent occlusion: thrombus horribilis | Q71518100 | ||
| Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention | Q71596506 | ||
| ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) | Q71724580 | ||
| ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myoc | Q71745548 | ||
| Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting | Q71774931 | ||
| One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non- | Q71827444 | ||
| Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors | Q71827452 | ||
| Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment | Q71848437 | ||
| Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction | Q71961062 | ||
| Diagnosing and managing unstable angina. Agency for Health Care Policy and Research | Q72047949 | ||
| Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators | Q72112987 | ||
| Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp | Q72122283 | ||
| Percutaneous transluminal coronary angioplasty | Q72276662 | ||
| Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia | Q72344109 | ||
| Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction | Q72352876 | ||
| Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials | Q72369172 | ||
| Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collabo | Q72665772 | ||
| Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group | Q72708506 | ||
| Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus | Q72786073 | ||
| Thrombin activity of fibrin thrombi and soluble plasmic derivatives | Q72788151 | ||
| Autoperfusion balloon versus stent for acute or threatened closure during percutaneous transluminal coronary angioplasty | Q72848216 | ||
| Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure | Q72893522 | ||
| Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction | Q73069470 | ||
| Stent thrombosis. Closing in on the best preventive treatment | Q73120249 | ||
| Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II | Q73368846 | ||
| Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study | Q73368849 | ||
| Platelet Integrin Glycoprotein IIb/IIIa Inhibitors: Opportunities and Challenges | Q73722384 | ||
| Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tiro | Q73744370 | ||
| Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate | Q73744392 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 183-197 | |
| P577 | publication date | 1998-11-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Management of Acute Ischemic Coronary Syndromes: The Present and Future | |
| P478 | volume | 6 |
| Q43615148 | Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs | cites work | P2860 |
Search more.